Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release

[Image: see text] Histone deacetylase inhibitors (HDACi) target abnormal epigenetic states associated with a variety of pathologies, including cancer. Here, the development of a prodrug of the canonical broad-spectrum HDACi suberoylanilide hydroxamic acid (SAHA) is described. Although hydroxamic aci...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniel, Kevin B., Sullivan, Eric D., Chen, Yao, Chan, Joshua C., Jennings, Patricia A., Fierke, Carol A., Cohen, Seth M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2015
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467547/
https://www.ncbi.nlm.nih.gov/pubmed/25974739
http://dx.doi.org/10.1021/acs.jmedchem.5b00539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467547/
https://www.ncbi.nlm.nih.gov/pubmed/25974739
http://dx.doi.org/10.1021/acs.jmedchem.5b00539

Ejemplares similares